Enveric Biosciences, Inc.
ENVB Nasdaq
SEC CIK 890821
Follow Enveric Biosciences
Weekly email: filings, results
Net income
−$2.5M
−36.1% vs same quarter last year
EPS, diluted
−$0.57
Operating cash flow
−$2.7M
−27.8% vs same quarter last year
Operating income
−$2.6M
−36.8% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | - | - |
| FY24 | - | - |
| FY23 | - | - |
| FY22 | - | −$18.5M |
| FY21 | - | −$49M |
| FY20 | - | −$6.9M |
| FY19 | $39.9M | −$2.4M |
| FY18 | $43M | −$16.9M |
| FY17 | $48.6M | −$9.1M |
| FY16 | $36.1M | −$2.8M |
| FY15 | $20.3M | −$814.1K |
| FY14 | $6.1M | $414.6K |
| FY13 | - | −$161 |
| FY12 | - | −$24.6K |
| FY11 | - | −$33.4K |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | - | - | - |
| FY24 | - | - | - |
| FY23 | - | - | - |
| FY22 | - | - | - |
| FY21 | - | - | - |
| FY20 | - | - | - |
| FY19 | 20.4% | −5.8% | −6% |
| FY18 | 20.9% | −16.6% | −39.3% |
| FY17 | 21.1% | −22.4% | −18.7% |
| FY16 | 19.2% | −14.9% | −7.7% |
| FY15 | 33.9% | −3.9% | −4% |
| FY14 | 14.8% | 10.2% | 6.7% |
| FY13 | - | - | - |
| FY12 | - | - | - |
| FY11 | - | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | - |
| FY24 | - |
| FY23 | −$14.1M |
| FY22 | −$17.7M |
| FY21 | −$11.6M |
| FY20 | - |
| FY19 | - |
| FY18 | - |
| FY17 | - |
| FY16 | - |
| FY15 | - |
| FY14 | - |
| FY13 | - |
| FY12 | - |
| FY11 | - |
- Enveric Biosciences
- Healthcare median
Show the numbers
| Year | Enveric Biosciences | Healthcare median |
|---|---|---|
| FY25 | - | −30.6% |
| FY24 | - | −47% |
| FY23 | - | −58% |
| FY22 | - | −80.4% |
| FY21 | - | −71.8% |
| FY20 | - | −62.2% |
| FY19 | −6% | −46.2% |
| FY18 | −39.3% | −49.6% |
| FY17 | −18.7% | −45.9% |
| FY16 | −7.7% | −36% |
| FY15 | −4% | −37.8% |
| FY14 | 6.7% | −35.5% |
| FY13 | - | −37.1% |
| FY12 | - | −29.1% |
| FY11 | - | −27.9% |